Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 8/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3980702 | 0.98 | HTT (0.54) | HTTSMN1; SMN2ALDH1A1LMNAGABRA5 | |
| SCHEMBL3979883 | 0.98 | HTT (0.54) | HTTSMN1; SMN2ALDH1A1LMNAGABRA5 | |
| SCHEMBL13842516 | 0.96 | HTT (0.53) | HTTSMN1; SMN2ALDH1A1LMNAGABRA5 | |
| SCHEMBL3982806 | 0.90 | HTT (0.58) | HTTSMN1; SMN2ALDH1A1LMNAGABRA5 | |
| SCHEMBL13842515 | 0.88 | HTT (0.61) | HTTSMN1; SMN2ALDH1A1LMNAGABRA5 | |
| SCHEMBL3975441 | 0.88 | HTT (0.56) | HTTSMN1; SMN2ALDH1A1LMNAGABRA5 | |
| SCHEMBL3977460 | 0.88 | HTT (0.65) | HTTSMN1; SMN2ALDH1A1LMNAGABRA5 | |
| SCHEMBL3977584 | 0.87 | HTT (0.56) | HTTSMN1; SMN2ALDH1A1LMNAKDM4E | |
| SCHEMBL3985247 | 0.86 | HTT (0.53) | HTTSMN1; SMN2ALDH1A1LMNAGABRA5 | |
| SCHEMBL3979229 | 0.86 | HTT (0.53) | HTTSMN1; SMN2ALDH1A1LMNAGABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538132-B2 | Isoxazolo derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538132-B2 | Isoxazolo derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-05-26 | — | — | US | disclosed |
| EP-1931661-B1 | ISOXAZOLO DERIVATIVES AS GABA A ALPHA5 INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-11-19 | — | — | EP | disclosed |
| US-20070066668-A1 | Isoxazolo derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-22 | — | — | US | disclosed |
| US-20070066668-A1 | Isoxazolo derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-22 | — | — | US | disclosed |
| US-20070066668-A1 | Isoxazolo derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066668-A1 | Isoxazolo derivatives | GABRA5, GABRA4, GABRA1 | HTT 2677/4885SMN1; SMN2 3215/4885ALDH1A1 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.